We’d love to hear your feedback on this activity. It helps us to continually improve our products.
A joint analysis of patients receiving immune checkpoint inhibitor therapy was conducted using the OnCovid (NCT04393974) and ESMO CoCARE registries, this assessed SARS-CoV-2 outcomes in vaccinated and unvaccinated patients with cancer and whether prior immune-related adverse events affected these outcomes. In this touchIMMUNOLOGY interview, we spoke with Dr Alessio Cortellini (Fondazione Policlinico Universitario Campus Bio-Medico, […]
The EULAR Coronavirus Vaccine (COVAX) physician-reported registry registered patients with pre-existing rheumatic and musculoskeletal diseases, who have been vaccinated against COVID-19. touchIMMUNOLOGY were delighted to speak with Prof Patrick Durez (Cliniques Universitaires Saint-Luc – Université Catholique de Louvain (UCL), Brussels, Belgium) to discuss the aims, methodology and findings of this study looking at factors associated […]
The GI-COVID-19 study (ClinicalTrials.gov NCT04691895) was a prospective, multicenter, controlled study investigating the prevalence of gastrointestinal (GI) symptoms in hospitalized patients with COVID-19. We were delighted to talk with Dr. Giovanni Marasco (Sant’Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy) to discuss the aims, methodology and findings in terms of prevalence of GI symptoms in patients with COVID-19 […]
The VIP study was a multicentre, prospective, case-control study, investigating whether immunosuppressive treatments reduced antibody and T-cell responses in patients with inflammatory bowel disease (IBD) after a third COVID-19 vaccine dose. In this touchIMMUNOLOGY interview, we speak with Dr. James Alexander (Imperial College London, London, UK) to discuss the aims, methodology and findings from the […]
In some countries, patients considered vulnerable have received 3rd/4th COVID-19 vaccine doses (V3/V4). This study, presented by Stavros Dimitriadis (University of Oxford, Oxford, UK), explores the immune response to V4 in a mixed disease cohort of immunosuppressed patients including liver transplant recipients and patients with autoimmune hepatitis. This study also focused on individuals with absent […]
We caught up with Dr James Alexander (Imperial College London, London, UK) to discuss the impact of immunosuppressant drugs on COVID-19 vaccine responses in patients with IBD. The abstract ‘COVID-19 vaccine-induced antibody responses are impaired in Inflammatory Bowel Disease patients treated with infliximab, ustekinumab or tofacitinib, but not thiopurines or vedolizumab’ (Presentation no. OP21) was […]
It was an absolute pleasure to speak with Dr David Pesqué (Universitat Autònoma de Barcelona, Barcelona, Spain) about his study investigating the skin reactions seen in response to mRNA COVID-19 vaccines. His presentation entitled ‘Clinical characterization of skin reactions due to mRNA COVID-19 vaccines at a tertiary-level hospital: a descriptive study’ was given at the EADV 30th Congress, 29 Sep- 2 Oct 2021. Questions What different types of skin reactions have been seen due to mRNA COVID-19 vaccines? (0:16) What is known about delayed cutaneous reactions? (1:20) What were the aims and protocol of your study? (2:41) What were the findings of the study? (3:54) Based on these findings, is there any reason to recommend alternative vaccines in certain patient groups? (5:25) Disclosures: Dr David Pesqué has nothing to disclose in relation to this video interview. Support: Interview and filming supported by Touch Medical Media. Interview conducted by Gina Furnival. Filmed in coverage of the EADV’s 30th Congress, 29 Sep – 2 Oct 2021. This content was developed by Touch Medical Media and is not affiliated with the European Academy of Dermatology & Venereology (EADV) or the congress.
It was a pleasure to speak with Prof. Nancy Reau (Rush Medical College, Chicago, IL, USA) about the hepatic manifestations of COVID-19 infection. Her presentation entitled ‘HEPATIC MANIFESTATIONS OF COVID-19: IS THERE CAUSE FOR CONCERN?’ was given at DDW, 21-23 May 2021 May 2021. Questions Could you give us a brief overview of the spectrum […]
We were delighted to talk to Corey Siegel (Dartmouth-Hitchcock Medical Center, Lebanon, NH, US) around the IOIBD consensus statement on SARS-CoV-2 vaccination in patients with IBD. Questions What issues were discussed at the consensus meeting of the International Organization for the Study of Inflammatory Bowel Disease (IOIBD) regarding the safety and effectiveness of SARS-CoV-2 vaccination […]
Get the latest clinical insights from touchIMMUNOLOGY